阿兰托拉克通过双重向糖原合成酶激酶3β和B细胞淋巴瘤抑制双重表达淋巴瘤2
Jianhua Chen1, Qing Liao1,2, Sha Yang1
1Department of Pharmacology Institute of Materia Medica, School of Pharmacy, North Sichuan Medical College, Nanchong, Sichuan, 637000, People's Republic of China.
Blood and lymphatic cancer : targets and therapy
|December 18, 2025
概括
阿兰托拉克 (ALA) 通过向GSK3β和BCL2两者,有效地抑制双表达淋巴瘤 (DEL) 的生长,提供了一个有前途的新治疗策略. 这种天然化合物抑制了瘤进展,并在临床前模型中延长了生存期,毒性最小.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 双表达性淋巴瘤 (DEL) 是一种具有不良预后和有限治疗选择的侵袭性癌症.
- 同时MYC和BCL2过度表达的特征是DEL,需要新的治疗方法.
- 一种天然化合物alantolactone (ALA) 显示出潜力,但其在DEL中的机制尚不清楚.
研究的目的:
- 研究ALA对DEL的抗瘤作用.
- 阐明DEL中ALA的双重准机制.
- 在临床前的DEL模型中评估ALA的疗效.
主要方法:
- 评估了LAA在淋巴瘤和正常细胞系中的细胞毒性活性.
- 利用网络药理学,分子对接和模拟来识别ALA目标.
- 使用CETSA验证了目标,并通过PET-CT成像在DEL异种移植中评估了体内疗效.
主要成果:
- 在体内,ALA抑制了DEL生长,毒性较低.
- ALA稳定了GSK3β,减少了Wnt驱动的瘤发生,并直接结合BCL2,诱导了亡.
- 在DEL异种移植中,ALA显著抑制了瘤进展和延长了存活时间.
结论:
- 通过对GSK3β和BCL2的双重向,ALA显示出强大的抗DEL活性.
- ALA 抑制瘤增殖并诱导亡,为 DEL 提供了一种新的治疗策略.
- ALA 是治疗这种耐火性淋巴瘤的有希望的多重向候选人.
更多相关视频
09:52A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
Published on: December 4, 2018
7.9K
11:55Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
14.9K
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K